Prolonged Survival in a Non-Small Cell Lung Cancer with Brain Metastasis Treated with a Brain Mass Evacuation and Gefi tinib

https://doi.org/10.22146/acta%20interna.22393

Mardiah Suci Hardianti(1*), Johan Kurnianda(2)

(1) 
(2) 
(*) Corresponding Author

Abstract


The incidence of brain metastasis (BM) is reported to be increase about 20-40% over the last few years in patients with non-small-cell lung cancer (NSCLC).1 The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in NSCLC patients with BM, especially those harboring EGFR mutations have been reported.

Keywords


Internal medicine; pulmonology; endocrinology; Internal Medicine; hematology and medical oncology; gastro entero hepatology; geriatric; rheumatology, cardiology

Full Text:

PDF


References

Wen PY, MB P, Loeffl er J. Metastatic Brain Cancer.Wen PY, MB P, Loeffl er J (Eds). Lippincott Williams and Wilkins, PA, USA,

Gaspar LE, Mehta MP, Patchell RA et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol . 2010. 96(1), 17–32.

Bartolotti M, Franceschi E, Brandes AA. EGF Receptor Tyrosine Kinase Inhibitors in the Treatment of Brain Metastases From Non-small-cell Lung Cancer. Expert Rev Anticancer Ther . 2012. 12(11):1429-1435.

Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 2007. 25(16), 2295–2305. 5. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P et al. Firstline erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012 Aug 20;30(24):3002-11

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A et al. Gefi tinib or Chemotherapy for Non– Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 2010;362:2380-8.

Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor

antagonists in non-small-cell lung cancer. J Clin Oncol. 2007 Feb 10. 25(5):587-95.

Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005 Mar. 2(3):e73.

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB et al. Sci Transl Med. 2011 March 23; 3(75): 75ra26.

doi:10.1126/scitranslmed.3002003.



DOI: https://doi.org/10.22146/acta%20interna.22393

Article Metrics

Abstract views : 250 | views : 73

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Acta Interna The Journal of Internal Medicine

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Acta Interna The Journal of Internal Medicine Indexed by:

 

 Indonesia Onesearch Google Scholar IPI Indonesian Publication Index

 website statistics View My Stats  

 

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.